To Enable Proper Dosing for Effective Treatment of Hemolytic Disease of the Fetus and Newborn (HDFN) in Africa

In Rhesus D hemolytic disease of the newborn, fetal red blood cells are destroyed by the maternal immune system through the placenta, causing devastating consequences for fetus (e.g., severe anemia, neurologic injury, stillbirth, and neonatal death) [1-2]. In African hospitals, the dose of the drug (an expensive and a potentially scarce blood product) given to patients is ad hoc, preventing effective treatment, exacerbating affordability, and hindering broad access of the drug in Africa [3-5].